Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.

Funding will support the final development phase prior to planned 2023 FDA submission of the company's "breakthrough" designated eNOcare™ hospital deviceWALTHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.Bill Athenson, CEO of Third Pole, stated, "We are thrilled to receive this investment, which raises Third Pole Therapeutics' series B financing and commitments to date to over $85M. I am particularly pleased to welcome this strategic investor and partner given our closely aligned missions. This investment and partnership will accelerate the entry of eNOcare™, our advanced portable inhaled nitric oxide (iNO) device, into the iNO hospital market." Mr. Athenson continued, "This significant investment in Third Pole Therapeutics follows considerable diligence of our engineering and regulatory readiness and serves as a strong endorsement of our technology and team's ability to deliver critical care systems that exceed safety and performance requirements established by regulatory bodies and the most demanding care professionals. We are targeting a 2023 FDA submission for our eNOcare™ hospital system into the existing and underpenetrated $600 million iNO hospital market."Bill Heiden, Third Pole's Chairman added, "This strategic investment in Third Pole Therapeutics is directly aligned with both organization's mission to advance unique, disruptive, cost-effective solutions that improve outcomes in heart and lung-failure patients

Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses.